Lessons from HIV therapy applied to viral hepatitis therapy

Summary of a workshop

Alexander Monto, Robert T. Schooley, Jennifer C. Lai, Mark Sulkowski, Raymond T. Chung, Jean Michel Pawlotsky, John G. McHutchison, Ira M. Jacobson

Research output: Contribution to journalArticle

Abstract

Therapies for hepatitis B virus (HBV) have continued to evolve, and new therapies for hepatitis C virus (HCV) will soon be available in clinical practice. These medications for hepatitis C will mark the first time that direct antivirals that target HCV functions have been used. When such drugs are used as single agents, previously existing mutants with reduced susceptibility to them are rapidly selected. The relationship between these drug-resistant mutants and wild-type virus is unclear, but resistant strains likely have the potential to maintain the progression of liver disease despite successful treatment of wild-type virus. Resistant HBV and now HCV are already a clinical problem. The same issue was recognized very early in the development of therapy against HIV, with azidothymidine-resistant mutants detected within the first weeks of therapy. Clinical investigation and a progressive understanding of the pathogenesis of the disease overcame this challenge and led to the substantial and durable benefits of antiretroviral therapy that are evident today. To bring experts from the fields of HIV and viral hepatitis virology and therapy together for interactive discussions about how to apply the lessons from HIV to the further development of viral hepatitis therapy, the American Association for the Study of Liver Diseases held a single-topic conference entitled Viral Hepatitis Therapy: Lessons to be Learned From HIV on 24-26 July 2008. This article summarizes that conference.

Original languageEnglish (US)
Pages (from-to)989-1004
Number of pages16
JournalAmerican Journal of Gastroenterology
Volume105
Issue number5
DOIs
StatePublished - May 2010

Fingerprint

Hepatitis
HIV
Education
Hepacivirus
Therapeutics
Hepatitis B virus
Viruses
Virology
Zidovudine
Hepatitis C
Pharmaceutical Preparations
Antiviral Agents
Liver Diseases

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Monto, A., Schooley, R. T., Lai, J. C., Sulkowski, M., Chung, R. T., Pawlotsky, J. M., ... Jacobson, I. M. (2010). Lessons from HIV therapy applied to viral hepatitis therapy: Summary of a workshop. American Journal of Gastroenterology, 105(5), 989-1004. https://doi.org/10.1038/ajg.2009.726

Lessons from HIV therapy applied to viral hepatitis therapy : Summary of a workshop. / Monto, Alexander; Schooley, Robert T.; Lai, Jennifer C.; Sulkowski, Mark; Chung, Raymond T.; Pawlotsky, Jean Michel; McHutchison, John G.; Jacobson, Ira M.

In: American Journal of Gastroenterology, Vol. 105, No. 5, 05.2010, p. 989-1004.

Research output: Contribution to journalArticle

Monto, A, Schooley, RT, Lai, JC, Sulkowski, M, Chung, RT, Pawlotsky, JM, McHutchison, JG & Jacobson, IM 2010, 'Lessons from HIV therapy applied to viral hepatitis therapy: Summary of a workshop', American Journal of Gastroenterology, vol. 105, no. 5, pp. 989-1004. https://doi.org/10.1038/ajg.2009.726
Monto, Alexander ; Schooley, Robert T. ; Lai, Jennifer C. ; Sulkowski, Mark ; Chung, Raymond T. ; Pawlotsky, Jean Michel ; McHutchison, John G. ; Jacobson, Ira M. / Lessons from HIV therapy applied to viral hepatitis therapy : Summary of a workshop. In: American Journal of Gastroenterology. 2010 ; Vol. 105, No. 5. pp. 989-1004.
@article{7c7f5cc910da4fac9aa55f79590379f0,
title = "Lessons from HIV therapy applied to viral hepatitis therapy: Summary of a workshop",
abstract = "Therapies for hepatitis B virus (HBV) have continued to evolve, and new therapies for hepatitis C virus (HCV) will soon be available in clinical practice. These medications for hepatitis C will mark the first time that direct antivirals that target HCV functions have been used. When such drugs are used as single agents, previously existing mutants with reduced susceptibility to them are rapidly selected. The relationship between these drug-resistant mutants and wild-type virus is unclear, but resistant strains likely have the potential to maintain the progression of liver disease despite successful treatment of wild-type virus. Resistant HBV and now HCV are already a clinical problem. The same issue was recognized very early in the development of therapy against HIV, with azidothymidine-resistant mutants detected within the first weeks of therapy. Clinical investigation and a progressive understanding of the pathogenesis of the disease overcame this challenge and led to the substantial and durable benefits of antiretroviral therapy that are evident today. To bring experts from the fields of HIV and viral hepatitis virology and therapy together for interactive discussions about how to apply the lessons from HIV to the further development of viral hepatitis therapy, the American Association for the Study of Liver Diseases held a single-topic conference entitled Viral Hepatitis Therapy: Lessons to be Learned From HIV on 24-26 July 2008. This article summarizes that conference.",
author = "Alexander Monto and Schooley, {Robert T.} and Lai, {Jennifer C.} and Mark Sulkowski and Chung, {Raymond T.} and Pawlotsky, {Jean Michel} and McHutchison, {John G.} and Jacobson, {Ira M.}",
year = "2010",
month = "5",
doi = "10.1038/ajg.2009.726",
language = "English (US)",
volume = "105",
pages = "989--1004",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Lessons from HIV therapy applied to viral hepatitis therapy

T2 - Summary of a workshop

AU - Monto, Alexander

AU - Schooley, Robert T.

AU - Lai, Jennifer C.

AU - Sulkowski, Mark

AU - Chung, Raymond T.

AU - Pawlotsky, Jean Michel

AU - McHutchison, John G.

AU - Jacobson, Ira M.

PY - 2010/5

Y1 - 2010/5

N2 - Therapies for hepatitis B virus (HBV) have continued to evolve, and new therapies for hepatitis C virus (HCV) will soon be available in clinical practice. These medications for hepatitis C will mark the first time that direct antivirals that target HCV functions have been used. When such drugs are used as single agents, previously existing mutants with reduced susceptibility to them are rapidly selected. The relationship between these drug-resistant mutants and wild-type virus is unclear, but resistant strains likely have the potential to maintain the progression of liver disease despite successful treatment of wild-type virus. Resistant HBV and now HCV are already a clinical problem. The same issue was recognized very early in the development of therapy against HIV, with azidothymidine-resistant mutants detected within the first weeks of therapy. Clinical investigation and a progressive understanding of the pathogenesis of the disease overcame this challenge and led to the substantial and durable benefits of antiretroviral therapy that are evident today. To bring experts from the fields of HIV and viral hepatitis virology and therapy together for interactive discussions about how to apply the lessons from HIV to the further development of viral hepatitis therapy, the American Association for the Study of Liver Diseases held a single-topic conference entitled Viral Hepatitis Therapy: Lessons to be Learned From HIV on 24-26 July 2008. This article summarizes that conference.

AB - Therapies for hepatitis B virus (HBV) have continued to evolve, and new therapies for hepatitis C virus (HCV) will soon be available in clinical practice. These medications for hepatitis C will mark the first time that direct antivirals that target HCV functions have been used. When such drugs are used as single agents, previously existing mutants with reduced susceptibility to them are rapidly selected. The relationship between these drug-resistant mutants and wild-type virus is unclear, but resistant strains likely have the potential to maintain the progression of liver disease despite successful treatment of wild-type virus. Resistant HBV and now HCV are already a clinical problem. The same issue was recognized very early in the development of therapy against HIV, with azidothymidine-resistant mutants detected within the first weeks of therapy. Clinical investigation and a progressive understanding of the pathogenesis of the disease overcame this challenge and led to the substantial and durable benefits of antiretroviral therapy that are evident today. To bring experts from the fields of HIV and viral hepatitis virology and therapy together for interactive discussions about how to apply the lessons from HIV to the further development of viral hepatitis therapy, the American Association for the Study of Liver Diseases held a single-topic conference entitled Viral Hepatitis Therapy: Lessons to be Learned From HIV on 24-26 July 2008. This article summarizes that conference.

UR - http://www.scopus.com/inward/record.url?scp=77951976606&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951976606&partnerID=8YFLogxK

U2 - 10.1038/ajg.2009.726

DO - 10.1038/ajg.2009.726

M3 - Article

VL - 105

SP - 989

EP - 1004

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -